FIELD: chemistry.
SUBSTANCE: present invention relates to compounds based on 3-(5-amino-1-oxoisoindolin-2-yl) piperidine-2,6-dione, specifically to a compound of formula (I'), where each of X1 and X2 is independently H or halogen; Rx is H; each of Ra and Rb is independently H, or Ra and Rb together with the atom to which they are attached form =(O); R1 is or ; R2 is H or (C1-C6) alkyl; or R5 is -OR6 or -NR7R7'; R6 is H, (C1-C6) alkyl, wherein alkyl is optionally substituted with one substituent independently selected from phenyl; each of R7 and R7' independently represents H, (C1-C6) alkyl, wherein alkyl is optionally substituted with one to three R8; or R7 and R7' together with the nitrogen atom to which they are attached form 5-member heterocycloalkyl ring; each R8 is -C(O)OH, (C3-C7) cycloalkyl, phenyl or 6-member heteroaryl containing 1 heteroatom selected from N, wherein cycloalkyl is optionally substituted with one to four R10; each R10 independently in each occurrence is (C1-C6) alkyl; n1 equals 1, 2 or 3; each of n2 and n3 independently equals 1; or its pharmaceutically acceptable salts. Invention also relates to a compound selected from a group of individual compounds, a pharmaceutical composition, a method for breaking down IKZF2, a method of treating a disease or disorder, a method of modulating IKZF2 protein levels, a method of reducing IKZF2 protein levels, use of the compound of formula (I') in the manufacture of a drug preparation for treating a disease or disorder, use of the compound of formula (I') in treating the disease or disorder.
EFFECT: obtaining novel compounds which can be used in treating diseases or disorders associated with zinc finger protein 2 of the IKAROS (IKZF2) family.
25 cl, 21 tbl, 34 ex
(I')
Title | Year | Author | Number |
---|---|---|---|
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
Authors
Dates
2024-03-20—Published
2019-07-08—Filed